Ensysce Biosciences, Inc. (ENSC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ensysce Biosciences, Inc. (ENSC) trades at $0.29 with AI Score 21/100 (Grade F). Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies. Market cap: $2.73M, Sector: Healthcare.
Price live · AI analysis from Jun 1, 2026ENSC stock analysis for 2026: Analysts have set a consensus price target of $16.45 for Ensysce Biosciences, Inc., suggesting 5491.4% upside from the current price of $0.29. The AI MoonshotScore is 21/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ENSC: 3/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Ensysce Biosciences, Inc. (ENSC) Healthcare & Pipeline Overview
Ensysce Biosciences, Inc. develops prescription drugs for severe pain relief and to prevent opioid addiction, misuse, abuse, and overdose. The company utilizes Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to create safer opioid alternatives, addressing a critical need in the healthcare sector.
What Is the Investment Thesis for ENSC?
Ensysce Biosciences presents a notable research candidate due to its innovative approach to addressing the opioid crisis with abuse-resistant and overdose-resistant prodrug technologies. The company's lead candidate, PF614, is in Phase II clinical trials and has the potential to become a safer alternative to traditional opioids for pain management. The MPAR platform offers an additional layer of protection against overdose, further enhancing the value proposition. Key catalysts include the progression of PF614 through clinical trials and potential partnerships for commercialization. However, the company's negative profit margin of -417.1% and gross margin of -72.9% highlight the financial risks associated with a clinical-stage pharmaceutical company. Successful clinical trial outcomes and strategic collaborations are critical for driving long-term value.
Based on FMP financials and quantitative analysis
ENSC Key Highlights
- Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing abuse-resistant and overdose-resistant opioid prodrugs.
- The company's lead product candidate, PF614, is a TAAP prodrug of oxycodone currently in Phase II clinical trials for the treatment of acute and chronic pain.
- Ensysce utilizes Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to enhance drug safety.
- The company is also developing PF614-MPAR, a combination product for overdose protection, currently in Phase I clinical trials.
- Ensysce's pipeline includes prodrugs for ADHD medication abuse (PF8001 and PF8026) and opioid use disorder (PF26810).
Who Are ENSC's Competitors?
ENSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| COLL Collegium Pharmaceutical, Inc. | $38.02 | +2.67% | $1.23B | 89 |
| TEVA Teva Pharmaceutical Industries Limited | $35.29 | +1.88% | $41.09B | 44 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENSC's Key Strengths?
- Innovative TAAP and MPAR technology platforms.
- Pipeline of abuse-resistant and overdose-resistant opioid prodrugs.
- Focus on addressing the opioid crisis.
- Experienced management team.
What Are ENSC's Weaknesses?
- Clinical-stage company with no approved products.
- High cash burn rate.
- Dependence on successful clinical trial outcomes.
- Small number of employees.
What Could Drive ENSC Stock Higher?
- Phase II clinical trial results for PF614.
- Phase I clinical trial results for PF614-MPAR.
- Development of PF329, an extended-release prodrug of hydromorphone.
- Research and development of PF8001 and PF8026 for ADHD medication abuse.
- Research and development of PF26810 for opioid use disorder.
What Are the Key Risks for ENSC?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for their drug candidates.
- Unsuccessful clinical trial outcomes.
- Competition from other pharmaceutical companies.
- Dependence on securing additional funding.
- Product liability lawsuits.
What Are the Growth Opportunities for ENSC?
- Advancement of PF614 through Clinical Trials: The successful completion of Phase II and Phase III clinical trials for PF614 will be a major growth driver. Positive results demonstrating efficacy and safety could lead to regulatory approval and commercialization. The market for non-abuse-deterrent opioids was estimated to be worth billions of dollars, suggesting a significant potential market for a safer alternative like PF614. Timeline: Anticipated Phase III trial completion within the next 2-3 years.
- Development and Commercialization of PF614-MPAR: The combination of PF614 with nafamostat for overdose protection offers a unique value proposition. Successful development and commercialization of PF614-MPAR could capture a significant share of the overdose prevention market. The increasing awareness and concern about opioid overdoses are driving demand for overdose reversal agents and prevention strategies. Timeline: Potential market entry within 3-5 years, pending clinical trial outcomes and regulatory approvals.
- Expansion of Pipeline with PF329 and Other Prodrugs: The development of PF329, an extended-release prodrug of hydromorphone, and other prodrugs for ADHD and opioid use disorder, diversifies Ensysce's product portfolio and reduces its reliance on a single product. These additional product candidates could address unmet needs in different therapeutic areas and expand the company's market reach. Timeline: Ongoing research and development with potential clinical trials commencing within the next 1-2 years.
- Partnerships and Collaborations: Strategic partnerships with pharmaceutical companies or research institutions could provide Ensysce with additional funding, expertise, and resources to accelerate the development and commercialization of its product candidates. Collaborations could also facilitate access to new markets and distribution channels. The biotechnology industry is characterized by collaborations and partnerships to share risks and rewards. Timeline: Ongoing efforts to establish partnerships and collaborations.
- Nafamostat for Coronaviral and Pulmonary Diseases: The exploration of nafamostat as an oral and inhalation drug product for coronaviral infections and other pulmonary diseases represents a potential new growth area for Ensysce. While this is outside the company's core focus on pain management and addiction treatment, it could provide a new revenue stream and diversify its business. The market for antiviral and pulmonary disease treatments is substantial and growing. Timeline: Ongoing research and development with potential clinical trials commencing within the next 1-2 years.
What Opportunities Does ENSC Have?
- Growing demand for safer pain management options.
- Increasing awareness of the opioid crisis.
- Potential for partnerships and collaborations.
- Expansion into new therapeutic areas.
What Threats Does ENSC Face?
- Regulatory hurdles and delays.
- Competition from other pharmaceutical companies.
- Patent challenges.
- Product liability lawsuits.
What Are ENSC's Competitive Advantages?
- Proprietary TAAP and MPAR technology platforms create a barrier to entry for competitors.
- Patent protection for their drug candidates provides exclusivity and market protection.
- Clinical trial data demonstrating the safety and efficacy of their products enhances their competitive position.
- First-mover advantage in the development of abuse-resistant and overdose-resistant opioid prodrugs.
What Does ENSC Do?
Ensysce Biosciences, Inc., founded in La Jolla, California, is a clinical-stage pharmaceutical company dedicated to developing innovative solutions for pain management and preventing opioid abuse and overdose. The company's core focus is on creating a new generation of opioid prodrugs that are both abuse-resistant and overdose-resistant, addressing the growing opioid crisis in the United States. Ensysce utilizes two primary technology platforms: Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). The TAAP platform is designed to prevent abuse by requiring the drug to be activated by trypsin, an enzyme found in the small intestine, making it difficult to abuse through snorting or injecting. The MPAR platform provides overdose protection by combining the opioid prodrug with a trypsin inhibitor, preventing the release of the opioid if too many pills are ingested. The company's lead product candidate, PF614, is a TAAP prodrug of oxycodone currently in Phase II clinical trials for treating acute and chronic pain. PF614-MPAR, a combination of PF614 and nafamostat, is in Phase I clinical trials for overdose protection. Ensysce is also developing PF329, an extended-release prodrug of hydromorphone, similar to PF614. Additionally, the company is working on PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse, and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce is also exploring the use of nafamostat as an oral and inhalation drug product for coronaviral infections and other pulmonary diseases, such as cystic fibrosis, further diversifying its pipeline.
What Products and Services Does ENSC Offer?
- Develop abuse-resistant opioid prodrugs using the Trypsin Activated Abuse Protection (TAAP) platform.
- Develop overdose-resistant opioid prodrugs using the Multi-Pill Abuse Resistance (MPAR) platform.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Seek regulatory approval from the FDA for their drug candidates.
- Commercialize their approved drug products through partnerships or direct sales.
- Research and develop new drug candidates for pain management, addiction treatment, and other therapeutic areas.
How Does ENSC Make Money?
- Develops pharmaceutical products focused on pain management and addiction.
- Generates revenue through potential future sales of approved drugs.
- Out-licenses or partners with other pharmaceutical companies for commercialization.
- Funds research and development through venture capital and grants.
What Industry Does ENSC Operate In?
Ensysce Biosciences operates within the biotechnology industry, specifically targeting the pain management and addiction treatment markets. The opioid crisis has created a significant need for safer and more effective pain relief options. The market for abuse-resistant opioid formulations is projected to grow as healthcare providers and regulatory agencies seek to reduce opioid-related deaths and addiction rates. Ensysce's TAAP and MPAR technologies position it to compete with other companies developing similar abuse-deterrent formulations, such as Collegium Pharmaceutical and Teva Pharmaceutical Industries. The company's success depends on its ability to navigate the complex regulatory landscape and demonstrate the clinical efficacy and safety of its product candidates.
Who Are ENSC's Key Customers?
- Patients suffering from acute or chronic pain.
- Healthcare providers who prescribe pain medication.
- Pharmacies that dispense pain medication.
- Hospitals and clinics that treat pain and addiction.
How Ensysce Biosciences, Inc. Is Valued
Ensysce Biosciences, Inc. carries a market capitalization of $2.73M, placing it in the micro-cap category. Relative to its peer group, ENSC's quantitative score of 21/100 is below the peer average of 73/100.
Company Profile
Ensysce Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. The company is led by CEO D. Lynn Kirkpatrick. ENSC has traded publicly since 2018.
F-Score 1/9Financial Health
Ensysce Biosciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project Ensysce Biosciences, Inc. revenue of about $6.8M for fiscal 2026, with EPS near $-1.98.
Net buyingInsider Activity
The most recent 12 insider filings for Ensysce Biosciences, Inc. break down as 0 sales and 12 purchases. On net that is roughly 1.7M shares acquired (about $1.7M) — insiders putting money in tends to read as conviction.
ENSC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of Ensysce's pain management solutions.
- Recent partnerships and collaborations have raised awareness and interest in Ensysce's drug development pipeline, attracting investor attention.
- The company's focus on addressing unmet medical needs positions it favorably in a growing market, enhancing its long-term appeal.
Bear Case
- Concerns about the company's cash flow and funding may overshadow its growth potential, leading to skepticism among investors.
- Some community members express doubts about the scalability of Ensysce's technologies, fearing they may not meet market demands.
- Recent regulatory challenges in the biotech sector have heightened caution, causing some investors to reconsider their positions in Ensysce.
- Market perception remains cautious, with lingering uncertainty about the timeline for product commercialization impacting sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ENSC Latest News
-
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga · Jul 2, 2026
-
Ensysce Biosciences Enrolls First Patient in Final Phase of Oral Overdose Study
MT Newswires · Jun 26, 2026
-
Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology
benzinga · Jun 26, 2026
-
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
accessnewswire.com · Jun 26, 2026
ENSC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENSC.
Price Targets
Consensus target: $16.45
ENSC MoonshotScore
What does this score mean?
The MoonshotScore rates ENSC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
Ensysce Biosciences Enrolls First Patient in Final Phase of Oral Overdose Study
Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Leadership: D. Lynn Kirkpatrick
CEO
D. Lynn Kirkpatrick has served as the CEO of Ensysce Biosciences, Inc. She has extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. Her background includes leadership roles in various biotechnology companies, where she has been involved in raising capital, managing clinical trials, and building strategic partnerships. She has a strong scientific background and a proven track record of bringing innovative products to market.
Track Record: Under D. Lynn Kirkpatrick's leadership, Ensysce Biosciences has advanced its pipeline of abuse-resistant and overdose-resistant opioid prodrugs through clinical trials. She has overseen the development of the TAAP and MPAR technology platforms and secured funding to support the company's research and development efforts. She has also established strategic partnerships to expand the company's reach and accelerate the commercialization of its products.
Ensysce Biosciences, Inc. Healthcare Stock: Key Questions Answered
What does Ensysce Biosciences, Inc. do?
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative solutions for pain management and preventing opioid abuse and overdose. The company utilizes its proprietary Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to create a new generation of opioid prodrugs that are designed to be abuse-resistant and overdose-resistant. Their lead product candidate, PF614, is currently in Phase II clinical trials for the treatment of acute and chronic pain. Ensysce aims to provide safer and more effective pain relief options while addressing the growing opioid crisis.
What do analysts say about ENSC stock?
As of June 1, 2026, there is limited analyst coverage available for ENSC stock due to its small market capitalization and clinical-stage nature. Investors should conduct their own due diligence and consider the risks associated with investing in a biotechnology company with no approved products. Key valuation metrics to consider include the potential market size for their drug candidates, the likelihood of successful clinical trial outcomes, and the company's cash runway. Growth considerations include the progression of their pipeline through clinical trials and potential partnerships for commercialization. No buy or sell recommendations are being made.
What are the main risks for ENSC?
The main risks for Ensysce Biosciences, Inc. include the inherent risks associated with clinical-stage pharmaceutical companies, such as the possibility of unsuccessful clinical trial outcomes and failure to obtain regulatory approval from the FDA. The company's high cash burn rate and dependence on securing additional funding also pose financial risks. Competition from other pharmaceutical companies developing similar products is another significant risk. Additionally, product liability lawsuits and patent challenges could negatively impact the company's business and financial performance. Investors should carefully consider these risks before investing in ENSC.
What is Ensysce Biosciences, Inc.'s drug pipeline status?
Ensysce Biosciences, Inc.'s drug pipeline includes PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain. PF614-MPAR, a combination product of PF614 and nafamostat, is in Phase I clinical trial for overdose protection against excessive oral ingestion. The company is also developing PF329, an extended-release prodrug of hydromorphone. Additionally, they are working on PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse, and PF26810, an extended-release prodrug of methadone for opioid use disorder. The pipeline focuses on leveraging TAAP and MPAR platforms to create safer alternatives to existing medications.
How does Ensysce Biosciences, Inc. address the opioid crisis?
Ensysce Biosciences, Inc. addresses the opioid crisis by developing abuse-resistant and overdose-resistant opioid prodrugs. Their TAAP technology makes it difficult to abuse the drugs through snorting or injecting, while their MPAR technology provides overdose protection by preventing the release of the opioid if too many pills are ingested. By creating safer alternatives to traditional opioids, Ensysce aims to reduce opioid-related deaths and addiction rates. Their product candidates have the potential to provide effective pain relief while minimizing the risk of abuse and overdose, addressing a critical need in the healthcare sector.
What are the key factors to evaluate for ENSC?
Ensysce Biosciences, Inc. (ENSC) holds an AI score of 21/100 (low). Analysts target $16.45 (+5491%). Not financial advice.
How frequently does ENSC data refresh on this page?
ENSC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ENSC's recent stock price performance?
Ensysce Biosciences, Inc. (ENSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative TAAP and MPAR technology platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is a clinical-stage pharmaceutical company and carries significant risks.